Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphoma: present and future challenges.

George P Canellos1

  • 1Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA. george_canellos@dfci.harvard.edu

Seminars in Hematology
|March 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Joseph R. Bertino, Scientist and Clinical Oncologist.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022
Same author

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.

The New England journal of medicine·2018
Same author

Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.

Tumori·2016
Same author

Advanced DLBCL: as systemic therapy improves, the need for RT diminishes.

Oncology (Williston Park, N.Y.)·2014
Same author

Treatment of Hodgkin lymphoma: a 50-year perspective.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014
Same author

Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited.

Oncology (Williston Park, N.Y.)·2013
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Advances in understanding cancer biology offer new lymphoma research avenues. However, optimal treatment standards for low-grade non-Hodgkin

Area of Science:

  • Oncology
  • Hematology
  • Cancer Biology

Background:

  • Significant advancements in understanding cancer cell biology have opened new research avenues for malignant lymphomas.
  • Despite progress, several critical challenges persist in lymphoma management.

Purpose of the Study:

  • To address the lack of a definitive standard of care for low-grade non-Hodgkin's lymphoma.
  • To evaluate if alternative regimens surpass current standards like CHOP for aggressive lymphomas.
  • To determine if treatments superior to ABVD exist for Hodgkin's disease and clarify the role of radiation therapy.

Main Methods:

  • Review of current treatment strategies and clinical trial data for malignant lymphomas.
  • Comparative analysis of established chemotherapy regimens (CHOP, ABVD) and radiation therapy protocols.

Related Experiment Videos

  • Identification of ongoing research and emerging therapeutic agents.

    • Main Results:

    • No single treatment strategy has emerged as superior for low-grade non-Hodgkin's lymphoma.
    • The efficacy of regimens beyond CHOP for aggressive lymphomas requires further investigation.
    • Optimal treatment protocols, including the role of radiation therapy for Hodgkin's disease, remain subjects of ongoing research.

    Conclusions:

    • Lymphoma management presents ongoing challenges, highlighting the need for continued research.
    • Development of novel therapeutic agents is crucial for improving patient outcomes in malignant lymphomas.
    • Further clinical trials are necessary to establish superior treatment standards for various lymphoma subtypes.